Pattern of Recurrence Changes in Noninvasive Bladder Tumors Observed During 2 Decades

Journal of Urology

Volumn 177, Issue 3, 2007, Pages 867-875

  Mariappan, Paramananthan ^a   Smith, Gordon ^a   Lamb, Alastair D G ^a   Grigor, Kenneth M ^a   Tolley, David A ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

bladder neoplasms; neoplasm staging; recurrence; risk assessment

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33846817520     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.10.048     Document Type: Article

References (15)

1. Holmang S., Hedelin H., Anderstrom C., and Johansson S.L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153 (1995) 1823
2. LeBlanc B., Duclos A.J., Bernard F., Cote J., Valiquette L., and Paquin J.M. Long-term follow up of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162 (1999) 1946
3. Oosterlinck W, van der Meijden A, Sylvester R, Bohle A, Rintala E, Solsona Narvon E et al: Guidelines on TaT1 (non-muscle invasive) bladder cancer (update 2006). European Association of Urology (EAU). Available at www.uroweb.org. Accessed April 2006.
4. Wright M.P.J., and Jones D.J. Surveillance for bladder cancer: the management of 4.8 million people. BJU Int 85 (2000) 431
5. Mariappan P., and Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173 (2005) 1108
6. Mariappan P., and Smith G. A similar surveillance schedule for G2Ta and G1Ta bladder tumours permits safe discharge at 5 years: results of a 25-year prospective database: P50. BJU Int 95 (2005) 53
7. Harmer M. TNM Classification of Malignant Tumours. 3rd ed. (1978), International Union Against Cancer, Geneva
8. Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G., Benyon L.L., Fellows J., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233
9. Cheng L., Neumann R.M., and Bostwick D.G. Papillary urothelial neoplasm of low malignant potential. Clinical and biological implications. Cancer 86 (1999) 2102
10. Fujii Y., Kawakami S., Koga F., Nemoto T., and Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 92 (2003) 559
11. Parmar M.K., Freedman L.S., Hargreave T.B., and Tolley D.A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142 (1989) 284
12. Thompson Jr. R.A., Campbell Jr. E.W., Kramer H.C., Jacobs S.C., and Naslund M.J. Late invasive recurrence despite long-term surveillance for superficial bladder. J Urol 149 (1993) 1010
13. Morris S.B., Gordon E.M., Shearer R.J., and Woodhouse C.R. Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?. Br J Urol 75 (1995) 193
14. Soloway M.S., Bruck D.S., and Kim S.S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170 (2003) 438
15. Konety B.R., and Getzenberg R.H. Urine based markers of urological malignancy. J Urol 165 (2001) 600